ViroPharma Continues Development Of Subcutaneous Cinryze Despite Setback
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma announced Aug. 1 that it is halting a Phase IIb study of a subcutaneous formulation of Cinryze with Halozyme’s recombinant human hyaluronidase (rHuPH20) due to safety concerns. Meanwhile, it reported 22% sales growth year-over-year for its hereditary angioedema drug in the U.S.